Factors Associated with Low IgG Response to mRNA COVID-19 Vaccine BNT162b2
Abstract Amid pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), vaccination is hailed as one of the most effective preventive measures. An mRNA vaccine termed BNT162b2 showed satisfactory safety and efficacy in the clinical trials but several issues including variability in the individual immune response or determination of target antibody titre that exerts sufficient immune protection needs to be assessed for planning a more efficient vaccination strategy. By monitoring IgG titres before and two months after the initial administration of BNT162b2 in 655 healthcare workers by Abbott IgG II quant that detects IgG against the receptor-binding domain in S protein of SARS-CoV-2, we confirmed that hypertension, dyslipidaemia, chronic kidney disease and use of immune suppressant in addition to male gender, advanced age, and absence of previous infection were significantly associated with low antibody response to the vaccination..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
ResearchSquare.com - (2022) vom: 16. Aug. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sugawa, Satoshi [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-969684/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA033784175 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA033784175 | ||
| 003 | DE-627 | ||
| 005 | 20230429184407.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220113s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-969684/v1 |2 doi | |
| 035 | |a (DE-627)XRA033784175 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-969684/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sugawa, Satoshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Factors Associated with Low IgG Response to mRNA COVID-19 Vaccine BNT162b2 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Amid pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), vaccination is hailed as one of the most effective preventive measures. An mRNA vaccine termed BNT162b2 showed satisfactory safety and efficacy in the clinical trials but several issues including variability in the individual immune response or determination of target antibody titre that exerts sufficient immune protection needs to be assessed for planning a more efficient vaccination strategy. By monitoring IgG titres before and two months after the initial administration of BNT162b2 in 655 healthcare workers by Abbott IgG II quant that detects IgG against the receptor-binding domain in S protein of SARS-CoV-2, we confirmed that hypertension, dyslipidaemia, chronic kidney disease and use of immune suppressant in addition to male gender, advanced age, and absence of previous infection were significantly associated with low antibody response to the vaccination. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Nishimura, Masashi |e verfasserin |4 aut | |
| 700 | 1 | |a Ota, Shinichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Morikawa, Miwa |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Shinoda, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ishii, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Kamachi, Kenichi |e verfasserin |4 aut | |
| 700 | 1 | |a Shinkai, Masaharu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2022) vom: 16. Aug. |
| 773 | 1 | 8 | |g year:2022 |g day:16 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-969684/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 16 |c 08 | ||